ImmPACT Bio to Present at Cell & Gene Meeting on the Mesa


ImmPACT Bio to Present at Cell & Gene Meeting on the Mesa


LOS ANGELES, Calif., October 3, 2023 – ImmPACT Bio USA, Inc. (“ImmPACT BIO”), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer and autoimmune diseases, today announced that it will participate at the 2023 Cell & Gene Meeting on the Mesa, being held October 10-12, 2023 in Carlsbad, CA.

Sumant Ramachandra, M.D., Ph.D., ImmPACT Bio’s president and chief executive officer, will present a corporate update and participate in a Q&A session on Wednesday, October 11, 2023 at 3:15 PM PT.

About ImmPACT Bio
ImmPACT Bio USA, Inc., is a clinical-stage company dedicated to the discovery of transformative chimeric antigen receptor (CAR) T-cell therapies that address key biological challenges in treating cancer and autoimmune diseases. The company’s logic-gate-based CAR T-cell platforms, licensed from University of California, Los Angeles (UCLA) Technology Development Group, are specifically designed to prevent antigen escape, overcome the immunosuppressive tumor microenvironment, and deplete pathogenic B cells. The company’s technology is based on the work of pioneering scientists Yvonne Chen, Ph.D., and Antoni Ribas, M.D., Ph.D., both from UCLA. For more information, visit

Contacts for inquiries or additional information:

For investors:

John Mullaly
LifeSci Advisors

For media:
Kathy Vincent
Greig Communications